MLEC vs PGEN

For growth investors, Moolec Science S.

A. (MLEC) is the stronger pick with 58. 3% revenue growth year-over-year, versus -36. 9% for Precigen, Inc. (PGEN). Analysts rate Precigen, Inc. (PGEN) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Moolec Science S.

A. (MLEC) delivered a total return of -8. 0%, compared to -36. 5% for Precigen, Inc. (PGEN). Over 10 years, the gap is even starker: MLEC returned -8. 5% versus PGEN's -84. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Moolec Science S.

A. (MLEC) is the lower-risk stock at 0. 89β versus Precigen, Inc. 's 1. 44β — meaning PGEN is approximately 62% more volatile than MLEC relative to the S&P 500.

By revenue growth (latest reported year), Moolec Science S.

A. (MLEC) is pulling ahead at 58. 3% versus -36. 9% for Precigen, Inc. (PGEN). On earnings-per-share growth, the picture is similar: Precigen, Inc. grew EPS -20. 5% year-over-year, compared to -89. 8% for Moolec Science S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Moolec Science S.

A. (MLEC) is the more profitable company, earning -33. 4% net margin versus -32. 2% for Precigen, Inc. — meaning it keeps -33. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MLEC leads at -3. 1% versus -34. 4% for PGEN. At the gross margin level — before operating expenses — MLEC leads at 34. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Moolec Science S.

A. (MLEC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 89)). Both have compounded well over 10 years (MLEC: -8. 5%, PGEN: -84. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MLEC is a small-cap high-growth stock; PGEN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.